New drug combo shows promise against advanced rectal cancer
NCT ID NCT02688712
First seen Apr 23, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests whether adding the experimental drug LY2157299 to standard chemotherapy and radiation can improve outcomes for people with locally advanced rectal cancer. About 50 adults will receive the combination over 8 weeks, and researchers will track tumor response and immune system changes for up to 5 years. The main goal is to see if the cancer disappears completely after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Cancer Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.